RE: Why sell NOW ? - Why NOT ?2 Feb 2021 13:57
Tiziana Life Sciences PLC (TLSA) is up over 50% at $5.89 in pre-market trading Tuesday, following positive data from the exploratory clinical study in Brazil investigating nasally administered Foralumab in COVID-19 patients.
Foralumab works by modulating the immune system and not by directly targeting COVID-19, and this therapeutic approach might also be useful for newly identified Covid-19 variants in UK, South Africa and Brazil, according to the company.